caa a22 4500 605491690 CHVBK 20210128100511.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s10147-014-0704-4 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0704-4 Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) [Elektronische Daten] [Shiro Saito, Kazuto Ito, Atsunori Yorozu, Manabu Aoki, Hirofumi Koga, Takefumi Satoh, Toshio Ohashi, Naoyuki Shigematsu, Shinichiro Maruo, Takashi Kikuchi, Shinsuke Kojima, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka] Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40% of all cases treated around the country. During the first 2years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89years (median 69years) and their risk classifications were 1,037 (44.3%) at low risk, 1,126 (48.1%) at intermediate risk, and 134 (5.7%) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6% were treated with PI without external beam radiation therapy and 49.3% received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40% of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up. Japan Society of Clinical Oncology, 2014 Brachytherapy nationallicence Iodine-125 nationallicence Multi-institutional prospective cohort study nationallicence Prostate cancer nationallicence Saito Shiro Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka Meguro-ku, 152-8902, Tokyo, Japan aut Ito Kazuto Department of Urology, Gunma University, Gunma, Japan aut Yorozu Atsunori Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan aut Aoki Manabu Department of Radiation Oncology, Jikei University School of Medicine, Tokyo, Japan aut Koga Hirofumi Department of Urology, Hara Sanshin Hospital, Fukuoka, Japan aut Satoh Takefumi Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan aut Ohashi Toshio Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan aut Shigematsu Naoyuki Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan aut Maruo Shinichiro Translational Research Informatics Center, Hyogo, Japan aut Kikuchi Takashi Translational Research Informatics Center, Hyogo, Japan aut Kojima Shinsuke Translational Research Informatics Center, Hyogo, Japan aut Dokiya Takushi Department of Radiation Oncology, Saitama Medical College, Saitama, Japan aut Fukushima Masanori Translational Research Informatics Center, Hyogo, Japan aut Yamanaka Hidetoshi Institutes of Preventive Medicine, Kurosawa Hospital, Gunma, Japan aut International Journal of Clinical Oncology Springer Japan 20/2(2015-04-01), 375-385 1341-9625 20:2<375 2015 20 10147 https://doi.org/10.1007/s10147-014-0704-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0704-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Saito Shiro Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka Meguro-ku, 152-8902, Tokyo, Japan aut NATIONALLICENCE 700 1- Ito Kazuto Department of Urology, Gunma University, Gunma, Japan aut NATIONALLICENCE 700 1- Yorozu Atsunori Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan aut NATIONALLICENCE 700 1- Aoki Manabu Department of Radiation Oncology, Jikei University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Koga Hirofumi Department of Urology, Hara Sanshin Hospital, Fukuoka, Japan aut NATIONALLICENCE 700 1- Satoh Takefumi Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan aut NATIONALLICENCE 700 1- Ohashi Toshio Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Shigematsu Naoyuki Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Maruo Shinichiro Translational Research Informatics Center, Hyogo, Japan aut NATIONALLICENCE 700 1- Kikuchi Takashi Translational Research Informatics Center, Hyogo, Japan aut NATIONALLICENCE 700 1- Kojima Shinsuke Translational Research Informatics Center, Hyogo, Japan aut NATIONALLICENCE 700 1- Dokiya Takushi Department of Radiation Oncology, Saitama Medical College, Saitama, Japan aut NATIONALLICENCE 700 1- Fukushima Masanori Translational Research Informatics Center, Hyogo, Japan aut NATIONALLICENCE 700 1- Yamanaka Hidetoshi Institutes of Preventive Medicine, Kurosawa Hospital, Gunma, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/2(2015-04-01), 375-385 1341-9625 20:2<375 2015 20 10147